Localized 1H-NMR spectroscopy in patients with fibromyalgia: A controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Fayed, Nicolas ^a   Garcia Campayo, Javier ^b,c   Magallón, Rosa ^c,d   Andrés Bergareche, Helena ^b   Luciano, Juan V ^c,e   Andres, Eva ^f   Beltrán, Julián ^a  

^a HOSPITAL QUIRÓN   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c Red de Investigacion en Actividades Preventivas y Promocion de la Salud en Atencion Primaria   (Spain)

^d INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^e PARC SANITARI SANT JOAN DE DÉU   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; ASPARTIC ACID; CHOLIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE; PROTON;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HIPPOCAMPUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PAIN; PAIN ASSESSMENT; PAIN CATASTROPHIZING SCALE; PAIN VISUAL ANALOG SCALE; PROTON NUCLEAR MAGNETIC RESONANCE; QUESTIONNAIRE; RATING SCALE; SENSORIMOTOR CORTEX; SPHYGMOMANOMETER; BRAIN; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE; PATHOLOGY; SOMATOSENSORY CORTEX;

ADULT; ASPARTIC ACID; BRAIN; CHOLIC ACID; CROSS-SECTIONAL STUDIES; DIFFUSION TENSOR IMAGING; FEMALE; FIBROMYALGIA; GLUTAMIC ACID; GLUTAMINE; HIPPOCAMPUS; HUMANS; INOSITOL; MALE; MIDDLE AGED; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PAIN; PROTONS; SOMATOSENSORY CORTEX;

EID: 77954265387     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3072     Document Type: Article

References (54)

1. Wolfe F, Smythe HA, Yunus MB, Bennet RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172. 10.1002/art.1780330203, 2306288.
2. Wolfe F, Ross K, Anderson J, Russell IJ. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28. 10.1002/art.1780380104, 7818567.
3. Wolfe F. Fibromyalgia, the clinical syndrome. Rheum Dis Clin North Am 1989, 15:1-18.
4. García Campayo J, Magdalena J, Magallón R, Fernandez-García E, Salas M, Andrés E. A meta-analysis of the efficacy of fibromyalgia treatment according to level of care. Arthritis Res Ther 2008, 10:R81. 10.1186/ar2455, 2575627, 18627602.
5. García Campayo J, Fayed N, Serrano-Blanco A, Roca M. Brain dysfunction behind functional symptoms: neuroimaging and somatoform, conversive, and dissociative disorders. Curr Opin Psychiatry 2009, 22:224-231. 10.1097/YCO.0b013e3283252d43, 19553880.
6. Jones AK, Brown WD, Friston KJ, Qi LY, Frackowiak RS. Cortical and subcortical localization of response to pain in man using positron emission tomography. Proc Biol Sci 1991, 244:39-44. 10.1098/rspb.1991.0048, 1677194.
7. Kwiatek R, Barnden L, Tedman R, Jarrett R, Chew J, Rowe C, Pile K. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000, 43:2823-2833. 10.1002/1529-0131(200012)43:12<2823::AID-ANR24≥3.0.CO;2-E, 11145042.
8. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46:1333-1343. 10.1002/art.10225, 12115241.
9. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004, 31:364-378.
10. Lutz J, Jäger L, de Quervain D, Krauseneck T, Padberg F, Wichnalek M, Beyer A, Stahl R, Zirngibl B, Morhard D, Reiser M, Schelling G. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis Rheum 2008, 58:3960-3969. 10.1002/art.24070, 19035484.
11. Hadjipavlou G, Dunckley P, Behrens TE, Tracey I. Determining anatomical connectivities between cortical and brainstem pain processing regions in humans: a diffusion tensor imaging study in healthy controls. Pain 2006, 123:169-178. 10.1016/j.pain.2006.02.027, 16616418.
12. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009, 60:3146-3152. 10.1002/art.24849, 19790053, 2827610.
13. Harris RE, Sundgren PC, Pang Y, Hsu M, Petrou M, Kim SH, McLean SA, Gracely RH, Clauw DJ. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008, 58:903-907. 10.1002/art.23223, 18311814.
14. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996, 111:209-219. 10.1006/jmrb.1996.0086, 8661285.
15. Jones DK, Williams SC, Gasston D, Horsfield MA, Simmons A, Howard R. Isotropic resolution diffusion tensor imaging with whole brain acquisition in a clinically acceptable time. Hum Brain Mapp 2002, 15:216-230. 10.1002/hbm.10018, 11835610.
16. Sundgren PC, Petrou M, Harris RE, Fan X, Foerster B, Mehrotra N, Sen A, Clauw DJ, Welsh RC. Diffusion-weighted and diffusion tensor imaging in fibromyalgia patients: a prospective study of whole brain diffusivity, apparent diffusion coefficient, and fraction anisotropy in different regions of the brain and correlation with symptom severity. Acad Radiol 2007, 14:839-846. 10.1016/j.acra.2007.03.015, 17574134.
17. Gordis L. Case-control and cross-sectional studies. Epidemiology 1996, 124-140. Philadelphia: WB Saunders, Gordis L.
18. Sullivan MJ, Bishop S, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess 1995, 7:524-532.
19. García Campayo J, Rodero B, Alda M, Sobradiel N, Montero J, Moreno S. Validación de la versión española de la Escala de Catastrofización ante el Dolor en la fibromialgia. Med Clin (Barc) 2008, 131:487-492. 10.1157/13127277, 19007576.
20. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
21. Tejero A, Guimerá EM, Farré JM, Peri JM. Uso clínico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. Rev Dep Psiquiatr Fac Med Barc 1986, 13:233-238.
22. Huskisson EC. Visual analog scales. Pain Measurement and Assessment 1983, 33-37. New York: Raven, Melzack R.
23. Vargas A, Vargas A, Hernández-Paz R, Sánchez-Huerta JM, Romero-Ramírez R, Amezcua-Guerra L, Kooh M, Nava A, Pineda C, Rodríguez-Leal G, Martínez-Lavín M. Sphygmomanometry-evoked allodynia: a simple bedside test indicative of fibromyalgia: a multicenter developmental study. J Clin Rheumatol 2006, 12:272-274. 10.1097/01.rhu.0000249770.86652.3b, 17149055.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6, 1202204.
25. Lobo A, Saz P, Marcos G, Día JL, de la Cámara C, Ventura T, Morales Asín F, Fernando Pascual L, Montañés JA, Aznar S. Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc) 1999, 112:767-774.
26. Burckhardt CS, Clark SR, Bennet RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
27. Rivera J, Gonzalez T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004, 22:554-560.
28. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000, 355:1696-1697. 10.1016/S0140-6736(00)02246-7, 10905250.
29. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, Reyes D, Shiung M, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Jack CR. Longitudinal 1 H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007, 28:1330-1339. 10.1016/j.neurobiolaging.2006.06.018, 2766807, 16860440.
30. Fayed N, Dávila J, Oliveros A, Medrano J, Castillo J. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment. Neurol Res 2010, 32:157-165. 10.1179/174313209X405164, 20158954.
31. Provencher SW. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679. 10.1002/mrm.1910300604, 8139448.
32. Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research. Brain Res Brain Res Rev 2004, 44:83-102. 10.1016/j.brainresrev.2003.11.001, 15003387.
33. Fayed N, Modrego PJ, Medrano J. Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain: the LCModel versus the manufacturer software. Neurol Res 2009, 31:472-477. 10.1179/174313209X395481, 19215666.
34. Coyle JT, Bird SJ, Evans RH, Gulley RL, Nadler JV, Nicklas WJ, Olney JW. Excitatory amino acid neurotoxins: selectively and mechanisms of action. Based on an NRP one-day conference held June 30, 1980. Neurosci Res Program Bull 1981, 19:1-427.
35. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233. 10.2174/187152707780619326, 17511618, 2918806.
36. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:969-995. 10.1016/j.pnpbp.2006.03.012, 16677749.
37. Dickenson AH. Gate Control Theory of pain stands the test of time. Br J Anaesth 2002, 88:755-757. 10.1093/bja/88.6.755, 12173188.
38. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009, 60:3146-3152. 10.1002/art.24849, 19790053, 2827610.
39. Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000, 32:1035-1038. 10.1016/S0168-8278(00)80110-5, 10898326.
40. Cordoba J, Blei AT. Brain edema and hepatic encephalopathy. Semin Liver Dis 1996, 16:271-280. 10.1055/s-2007-1007240, 8989813.
41. Mullins PG, Rowland LM, Jung RE, Sibbitt WL. A novel technique to study the brain's response to pain: proton magnetic resonance spectroscopy. Neuroimage 2005, 26:642-646. 10.1016/j.neuroimage.2005.02.001, 15907322.
42. Córdoba J, Sanpedro F, Alonso J, Rovira A. 1 H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002, 17:415-429. 10.1023/A:1021926405944, 12602517.
43. Bosman DK, Deutz NE, De Graaf AA, Van der Hulst RWN, Van Eijk HM, Bovee WM. Changes in brain metabolism during hyperammonemia and acute liver failure: results of a comparative 1 H NMR spectroscopy and biochemical investigation. Hepatology 1990, 12:281-290. 10.1002/hep.1840120215, 1975248.
44. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992, 182:19-27.
45. Petrou M, Harris RE, Foerster BR, McLean SA, Sen A, Clauw DJ, Sundgren PC. Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fibromyalgia: comparison with healthy controls and correlation with symptom severity. AJNR Am J Neuroradiol 2008, 29:913-918. 10.3174/ajnr.A0959, 18339723.
46. Wood PB, Ledbetter CR, Glabus MF, Broadwell LK, Patterson JC. Hippocampal metabolite abnormalities in fibromyalgia: correlation with clinical features. J Pain 2009, 10:47-52.
47. Emad Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker JJ. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome: a study with single-voxel magnetic resonance spectroscopy. J Rheumatol 2008, 35:1371-1377.
48. Ogura A, Miyamoto M, Kudo Y. Neuronal death in vitro: parallelism between survivability of hippocampal neurones and sustained elevation of cytosolic Ca2+ after exposure to glutamate receptor agonist. Exp Brain Res 1988, 73:447-458. 10.1007/BF00406601, 2906295.
49. Mattson MP, Murrain M, Guthrie PB, Kater SB. Fibroblast growth factor and glutamate: opposing roles in the generation and degeneration of hippocampal neuroarchitecture. J Neurosci 1989, 9:3728-3740.
50. McKenna JE, Melzack R. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp Neurol 2001, 172:92-99. 10.1006/exnr.2001.7777, 11681843.
51. Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005, 7:1-10. 10.1111/j.1399-5618.2004.00174.x, 15654927.
52. Harwood AJ. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry 2005, 10:117-126. 10.1038/sj.mp.4001618, 15558078.
53. Barkai IA, Dunner DL, Gross HA, Mayo P, Fieve RR. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 1978, 13:65-72.
54. Gormsen L, Rosenberg R, Bach FW, Jensen TS. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain 2010, 14:127. e1-8, 10.1016/j.ejpain.2009.03.010, 19473857.